Market Access
Working to make appropriate BD technologies available on a sustainable basis.
To strengthen healthcare systems in the developing world, BD Global Health makes critical technologies available on an affordable basis. These products—including diagnostic tools and medical devices—improve the rational use of medicine and delivery of healthcare in resource-limited settings.
BD has a long-standing relationship with the Foundation for Innovative New Diagnostics (FIND), designed to improve the diagnosis of pulmonary tuberculosis, which is the leading cause of death for people living with AIDS in developing countries. BD and FIND established demonstration sites in Africa, Eastern Europe and Asia to introduce advanced culture technology for rapid diagnosis and drug sensitivity testing of TB. BD and FIND have since expanded their agreement to include funding for laboratory strengthening and a pricing agreement for the BD BACTEC™ MGIT™ system.
Since 2002, BD has been in a partnership with the Clinton Health Access Initiative (CHAI) to expand access to CD4 testing in Africa, Asia, Latin America and Eastern Europe, and to provide deeply discounted pricing (of up to nearly 75%). More recently, BD and CHAI are partnering on a CD4 access solution to ensure appropriate instruments are placed at various levels of the healthcare system, enabling governments to efficiently manage changing dynamics in the HIV & AIDS staging and monitoring market.